- Glaukos Corporation GKOS shares have gained as investors cheer the final physician payment rates and outpatient facility fees issued by the Centers for Medicare & Medicaid Services (CMS) for 2022.
- See the 8K filing on the update.
- After the CMS published the Final Rule, Stephens has upgraded Glaukos to Overweight from Equal Weight, with a price target of $68, up from $60.
- The analyst Chris Cooley noted a favorable reimbursement outlook for devices used for micro-invasive glaucoma surgery (MIGS).
- According to Piper Sandler, Glaukos is a 'big beneficiary' of the final CMS ruling.
- Analyst Matt O'Brien tells investors that the Company's facility cut has been largely reversed and its physician cut reduced.
- Related: William Blair Downgrades Glaukos After Disappointing CMS Rate; Shares Drop.
- Price Action: GKOS shares are up 20.8% at $54.45 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in